- Home
- AFRI vs ACRS Comparison
AFRI vs ACRS Comparison
Compare AFRI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- ACRS
- Stock Information
- Founded
- AFRI 1943
- ACRS 2012
- Country
- AFRI Gibraltar
- ACRS United States
- Employees
- AFRI N/A
- ACRS N/A
- Industry
- AFRI Packaged Foods
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- ACRS Health Care
- Exchange
- AFRI Nasdaq
- ACRS Nasdaq
- Market Cap
- AFRI 207.7M
- ACRS 198.2M
- IPO Year
- AFRI N/A
- ACRS 2015
- Fundamental
- Price
- AFRI $8.60
- ACRS $1.96
- Analyst Decision
- AFRI
- ACRS Strong Buy
- Analyst Count
- AFRI 0
- ACRS 9
- Target Price
- AFRI N/A
- ACRS $9.25
- AVG Volume (30 Days)
- AFRI 6.0K
- ACRS 1.0M
- Earning Date
- AFRI 04-30-2025
- ACRS 11-05-2025
- Dividend Yield
- AFRI N/A
- ACRS N/A
- EPS Growth
- AFRI N/A
- ACRS N/A
- EPS
- AFRI N/A
- ACRS N/A
- Revenue
- AFRI $274,223,000.00
- ACRS $16,789,000.00
- Revenue This Year
- AFRI N/A
- ACRS N/A
- Revenue Next Year
- AFRI N/A
- ACRS $7.02
- P/E Ratio
- AFRI N/A
- ACRS N/A
- Revenue Growth
- AFRI N/A
- ACRS N/A
- 52 Week Low
- AFRI $7.47
- ACRS $1.05
- 52 Week High
- AFRI $11.20
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- AFRI 51.47
- ACRS 50.97
- Support Level
- AFRI $8.13
- ACRS $1.74
- Resistance Level
- AFRI $8.73
- ACRS $2.10
- Average True Range (ATR)
- AFRI 0.23
- ACRS 0.11
- MACD
- AFRI -0.04
- ACRS 0.00
- Stochastic Oscillator
- AFRI 54.83
- ACRS 48.60
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.